11, 13-Dehydro Lactone Moiety in Gynecologic Cancer Cells

Cancer Immunity 13:11 (2013)

Buffalo, Buffalo, NY, USA 2The Jackson Laboratory, Bar Harbor, ME, USA 3Department of Gynecologic Oncology, Roswell Park Cancer Institute, Buffalo, NY, USA 4Department of Microbiology and Immunology, University of Rochester, School of Medicine and Dentistry, Rochester, NY, USA 5Department of Pharmaceutical Sciences, The State University of New York at Buffalo, Buffalo, NY, USA May 2013) Vol. 13...

Regulatory T Cells in Gynecologic Cancer

Understanding the role of the immune system in the control of cancer growth has been a field of intense investigation over the past decades. The advances in the knowledge of the immune system has led to the view of it as a dual role player in suppressing tumor growth and facilitating tumor progression. The studies in murine models identified tumors as sites of immune tolerance based on the obse...

Hereditary Factors in Gynecologic Cancer.

Cancer predisposition in some families is known to be the result of germ-line mutations. The most noteworthy hereditary gynecologic cancer syndromes include hereditary breast-ovarian cancer (HBOC) syndrome, wherein BRCA1 and BRCA2 germ-line mutations have been identified, and hereditary nonpolyposis colorectal cancer (HNPCC) of the Lynch syndrome II variant, wherein hMSH2, hMLH1, hPMS2, hMSH3, ...

Global cooperation in gynecologic cancer.

Pelvic Exenteration in Gynecologic Cancer

Background: Pelvic exenteration is an ultraradical surgery involving the en bloc resection of the pelvic organs, including the internal reproductive organs, the distal urinary tract (ureters, bladder, urethra), and/or anorectum. It is mainly applied as a salvage surgery for recurrent gynecologic tumors of any origin (vulva, vagina, cervix, uterine, and also ovary). Our aim was to establish the ...